Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Faricimab - Roche

Next Previous
X
Search
Drug Profile

Faricimab - Roche

Alternative Names: Faricimab-svoa; RG 7716; RO 6867461; Vabysmo

Latest Information Update: 01 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Genentech; Roche
  • Class Bispecific antibodies; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
  • Preregistration Diabetic retinopathy
  • Phase III Angioid streaks; Choroidal neovascularisation
  • Clinical Phase Unknown Polypoidal choroidal vasculopathy

Most Recent Events

  • 30 Jul 2024 Launched for Retinal oedema in Norway, Hungary, Czech Republic (Intravitreous)
  • 30 Jul 2024 Registered for Retinal oedema in European Union, Liechtenstein, Norway, Iceland (Intravitreous)
  • 29 Jul 2024 Launched for Diabetic macular oedema in Canada (Intravitreous) prior to July 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top